These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 29947936)

  • 1. [Treatment of chronic migraine with botulinum neurotoxin A : Expert recommendations of the German Migraine and Headache Society].
    Ruscheweyh R; Förderreuther S; Gaul C; Gendolla A; Holle-Lee D; Jürgens T; Neeb L; Straube A
    Nervenarzt; 2018 Dec; 89(12):1355-1364. PubMed ID: 29947936
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Botulinum neurotoxin for the treatment of migraine and other primary headache disorders.
    Blumenfeld AM; Dodick DW; Silberstein SD
    Dermatol Clin; 2004 Apr; 22(2):167-75. PubMed ID: 15222577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Botulinum toxin: A review of the mode of action in migraine.
    Do TP; Hvedstrup J; Schytz HW
    Acta Neurol Scand; 2018 May; 137(5):442-451. PubMed ID: 29405250
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Self-medication of migraine and tension-type headache: summary of the evidence-based recommendations of the Deutsche Migräne und Kopfschmerzgesellschaft (DMKG), the Deutsche Gesellschaft für Neurologie (DGN), the Österreichische Kopfschmerzgesellschaft (ÖKSG) and the Schweizerische Kopfwehgesellschaft (SKG).
    Haag G; Diener HC; May A; Meyer C; Morck H; Straube A; Wessely P; Evers S; ; ; ;
    J Headache Pain; 2011 Apr; 12(2):201-17. PubMed ID: 21181425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
    Suzuki K; Iizuka T; Sakai F
    Intern Med; 2007; 46(13):959-63. PubMed ID: 17603233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Duration of migraine is a predictor for response to botulinum toxin type A.
    Eross EJ; Gladstone JP; Lewis S; Rogers R; Dodick DW
    Headache; 2005 Apr; 45(4):308-14. PubMed ID: 15836566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers.
    Tassorelli C; Aguggia M; De Tommaso M; Geppetti P; Grazzi L; Pini LA; Sarchielli P; Tedeschi G; Martelletti P; Cortelli P
    J Headache Pain; 2017 Dec; 18(1):66. PubMed ID: 28667550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Botulinum toxin type a for chronic migraine.
    Ashkenazi A
    Curr Neurol Neurosci Rep; 2010 Mar; 10(2):140-6. PubMed ID: 20425239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Botulinum neurotoxin A for chronic migraine headaches: does it work and how?
    Cairns BE; Gazerani P
    Pain Manag; 2014; 4(6):377-80. PubMed ID: 25494688
    [No Abstract]   [Full Text] [Related]  

  • 10. Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT.
    Silberstein SD; Dodick DW; Aurora SK; Diener HC; DeGryse RE; Lipton RB; Turkel CC
    J Neurol Neurosurg Psychiatry; 2015 Sep; 86(9):996-1001. PubMed ID: 25500317
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Botulinum neurotoxin--a therapy in migraine].
    Tajti J; Szok D; Tuka B; Csáti A; Kuris A; Majláth Z; Lukács M; Vécsei L
    Ideggyogy Sz; 2012 Mar; 65(3-4):77-82. PubMed ID: 23136725
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation.
    Bendtsen L; Sacco S; Ashina M; Mitsikostas D; Ahmed F; Pozo-Rosich P; Martelletti P
    J Headache Pain; 2018 Sep; 19(1):91. PubMed ID: 30259200
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum Toxin Type a as a Therapeutic Agent against Headache and Related Disorders.
    Luvisetto S; Gazerani P; Cianchetti C; Pavone F
    Toxins (Basel); 2015 Sep; 7(9):3818-44. PubMed ID: 26404377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization.
    Mitchell MP; Schaecher K; Cannon HE; Speckman M
    J Manag Care Pharm; 2008 Jun; 14(5):442-50. PubMed ID: 18597573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy, safety, and predictors of response to botulinum toxin type A in refractory chronic migraine: a retrospective study.
    Lin KH; Chen SP; Fuh JL; Wang YF; Wang SJ
    J Chin Med Assoc; 2014 Jan; 77(1):10-5. PubMed ID: 24269600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Botox Right for Me: When to Assess the Efficacy of the Botox Injection for Chronic Migraine in Pediatric Population.
    Goenka A; Yu SG; George MC; Chikkannaiah M; MacDonald S; Stolfi A; Kumar G
    Neuropediatrics; 2022 Oct; 53(5):344-350. PubMed ID: 35453165
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of two different botulinum toxin type A dilutions in chronic migraineurs.
    Tereshko Y; Lettieri C; Belgrado E; Pez S; Gigli GL; Valente M
    Toxicon; 2023 May; 227():107096. PubMed ID: 36965713
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Botulinum toxin type a for the prophylaxis of chronic daily headache: subgroup analysis of patients not receiving other prophylactic medications: a randomized double-blind, placebo-controlled study.
    Dodick DW; Mauskop A; Elkind AH; DeGryse R; Brin MF; Silberstein SD;
    Headache; 2005 Apr; 45(4):315-24. PubMed ID: 15836567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monocentric Prospective Study into the Sustained Effect of Incobotulinumtoxin A (XEOMIN
    Ion I; Renard D; Le Floch A; De Verdal M; Bouly S; Wacongne A; Lozza A; Castelnovo G
    Toxins (Basel); 2018 Jun; 10(6):. PubMed ID: 29857565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of preventive treatment with botulinum toxin type A on acute headache medication usage in migraine patients.
    Schim J
    Curr Med Res Opin; 2004 Jan; 20(1):49-53. PubMed ID: 14741072
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.